Latest News of ABBV
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance |
3 days ago
The pharmaceutical industry is booming, with a focus on innovative research and development. AbbVie Inc. is one of the top pharma stocks to watch. Advances in medical technology and AI are transformin...
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
By Yahoo! Finance |
1 week ago
AbbVie reported quarterly earnings of $3 per share, beating estimates. The company's revenue also exceeded expectations. With a strong performance, investors await management's guidance for future gro...
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi
By Investor's Business Daily |
1 week ago
AbbVie (ABBV) stock rose as it reported Q3 earnings of $3 per share on $14.46 billion in sales, beating analyst estimates. Sales of new drugs Skyrizi and Rinvoq surpassed expectations, with Skyrizi ou...
-
Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?
By Yahoo! Finance | 1 week agoDavid Iben emphasized that avoiding permanent loss of capital is more crucial than volatility. Debt can be risky for a company, leading to bankruptcy or dilution of shareholders. Assessing a company's...
-
AbbVie's Bold $1.4 Billion Bet: The Alzheimer's Breakthrough Investors Have Been Waiting For
By Yahoo! Finance | 1 week agoAbbVie's strategic acquisition of Aliada Therapeutics for $1.4 billion is a significant move into Alzheimer's innovation. The acquisition enhances AbbVie's R&D capabilities with cutting-edge technolog...
-
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
By Yahoo! Finance | 2 weeks agoThe U.S. FDA has approved AbbVie's VYALEV, a continuous levodopa infusion for advanced Parkinson's disease. Studies show improved motor symptom management compared to oral medication....
-
AbbVie price target raised to $220 from $214 at BMO Capital
By Yahoo! Finance | 2 weeks agoBMO Capital raised AbbVie's price target to $220 from $214, maintaining an Outperform rating. Skyrizi and Rinvoq are key growth drivers in AbbVie's portfolio, exceeding Q3 growth expectations....
-
Jim Cramer Says AbbVie Inc. (ABBV) 'Is Doing Very, Very Well'
By Yahoo! Finance | 3 weeks agoAn article discusses Jim Cramer's insights on market volatility and advises against impulsive trading based on earnings reactions. AbbVie Inc....
-
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
By Yahoo! Finance | 3 weeks agoThe FDA approved AbbVie's Vyalev for advanced Parkinson's disease, providing a 24-hour subcutaneous infusion of levodopa therapy. The treatment showed superior results in improving motor fluctuations ...
-
Is AbbVie Inc. (NYSE:ABBV) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?
By Yahoo! Finance | 4 weeks agoGoldman Sachs' list of popular stocks among mutual fund managers ranks AbbVie Inc. (NYSE:ABBV) 8th. Despite market fluctuations, the firm's financial strength and diverse product portfolio position it...
-
PGIM Jennison Health Sciences Fund Sold AbbVie (ABBV) in Q2. Here's Why
By Yahoo! Finance | 1 month agoThe PGIM Jennison Health Sciences Fund's Q2 2024 investor letter highlighted its performance and top holdings, including AbbVie Inc. (NYSE:ABBV), a pharmaceutical company. The fund underperformed slig...
-
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
By MarketWatch | 1 month agoAbbVie seeks accelerated FDA approval for teliso-V, an antibody-drug conjugate for c-Met overexpressing non-small cell lung cancer. This treatment targets a specific group of patients with a poor prog...
-
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
By Yahoo! Finance | 1 month agoAbbVie's drug, tavapadon, successfully met the main goal in a late-stage trial for early Parkinson's disease. Patients showed improvement compared to placebo, as evaluated on a disease rating scale....
-
Bausch Reportedly Eyes A Sale; Could J&J Or AbbVie Buy It?
By Investor's Business Daily | 1 month agoBausch + Lomb stock surged amid reports of a potential sale, with private equity seen as the likely buyer due to antitrust challenges for other companies. The parent company, Bausch Health, faces pate...
-
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
By Yahoo! Finance | 1 month agoAbbVie, known for its strong dividend growth, faces challenges post-Humira patent expiration. Despite slower dividend growth, its pipeline and acquisitions offer hope for recovery. Investors should mo...